X0609 4 2026-08-28 0001635088 Roivant Sciences Ltd. ROIV 0001801917 Venker Eric true C/O ROIVANT SCIENCES LTD. 7TH FLOOR, 50 BROADWAY LONDON X0 SW1H 0DB UNITED KINGDOM true President & Immunovant CEO true Common Shares 2026-08-28 4 M 0 200000 3.85 A 1799154 D Common Shares 2026-08-28 4 S 0 166182 35.63 D 1632972 D Common Shares 2026-08-28 4 S 0 33818 36.44 D 1599154 D Stock Option (Right to Buy) 3.85 2026-08-28 4 M 0 200000 0 D 2032-04-19 Common Stock 200000 3844834 D The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.17 to $36.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.17 to $36.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025. Reflects an award of stock options to purchase Common Shares that is fully vested. By: /s/ Sam Kaplan, as Attorney-in-Fact for Eric Venker 2026-09-01